SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-22-002955
Filing Date
2022-02-02
Accepted
2022-02-02 09:00:12
Documents
14
Period of Report
2022-01-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 48022
2 ex10-1.htm EX-10.1 55147
3 ex10-2.htm EX-10.2 43911
  Complete submission text file 0001493152-22-002955.txt   335436

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE otlc-20220131.xsd EX-101.SCH 3036
5 XBRL LABEL FILE otlc-20220131_lab.xml EX-101.LAB 34476
6 XBRL PRESENTATION FILE otlc-20220131_pre.xml EX-101.PRE 22597
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 2943
Mailing Address 29397 AGOURA RD. #107 AGUORA HILLS CA 91301
Business Address 29397 AGOURA RD. #107 AGUORA HILLS CA 91301 650-635-7000
Oncotelic Therapeutics, Inc. (Filer) CIK: 0000908259 (see all company filings)

IRS No.: 133679168 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21990 | Film No.: 22581654
SIC: 2834 Pharmaceutical Preparations